...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients.
【24h】

Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients.

机译:Viscum Album提取物Isorel在消化道癌症患者的围手术期应用。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: It is assumed that perioperative immunomodulation of cancer patients can attenuate cellular and humoral deficiencies thus improving their overall health status. Mistletoe (Viscum album L.) anticancer drugs are likely candidates for such adjuvant therapy, because they do not have major adverse side-effects but have dual desirable activities; immune-modulating effects and relatively selective cytotoxicity for cancer cells. MATERIALS AND METHODS: We used the aqueous extract Isorel, which is produced from the entire plant and is validated for batch consistency. The study involved 70 cancer patients, divided into two groups: Isorel-treated group of 40 patients who received Isorel for 2 pre- and 2 post-operative weeks (1 esophageal, 16 gastric, 2 pancreatic and 21 colorectal carcinomas) and the age- and sex-matched control group of 30 patients that did not receive Isorel (2 esophageal, 9 gastric, 3 pancreatic, 1 ileac and 15 colorectal carcinomas). Blood samples were obtained to study parameters of the immune system before the surgery and the drug administration (DO) and on the postoperative days 1 and 14 (D1, D14). The overall health status was evaluated after 60 days by the Kamofsky Performance Index and by the Analogic Scale of Anxiety. The results were compared by Student's t-test and one-way ANOVA test. RESULTS: Isorel significantly attenuated the immuno-suppressive effects of surgery observed for the Isorel-treated group, increasing the number of NK cells, the T and B cells, in particular T-helper cells, complement, IgA, IgG and IgM values also in comparison to the respective D0 values. Both the Kamofsky status and the Anxiety Scale improved remarkably in Isorel-treated patients in comparison to the control. CONCLUSION: The results of this study indicate that perioperative use of the mistletoe drug Isorel can improve immune competence and the overall health status of cancer patients undergoing surgery.
机译:背景:人们认为癌症患者的围手术期免疫调节可以减轻细胞和体液的缺乏,从而改善他们的整体健康状况。槲寄生(Viscum album L.)抗癌药可能是此类辅助治疗的候选药物,因为它们没有主要的不良副作用,但具有双重理想的活性。癌细胞的免疫调节作用和相对选择性的细胞毒性。材料和方法:我们使用了提取液Isorel,该提取物是从整个工厂生产的,并已验证批次的一致性。这项研究涉及70位癌症患者,分为两组:Isoreel治疗组的40位患者在手术前和术后2周接受了Isorel治疗(1例食道癌,16例胃癌,2例胰腺癌和21例结直肠癌),年龄分别为-性别匹配的对照组,其中30例未接受Isorel的患者(2例食道癌,9例胃癌,3例胰腺癌,1例回肠癌和15例大肠癌)。在手术和药物管理(DO)之前以及术后第1天和第14天(D1,D14)获取血液样本以研究免疫系统的参数。 60天后通过卡莫夫斯基绩效指数和焦虑类似量表评估总体健康状况。通过学生t检验和单向ANOVA检验比较结果。结果:Isoreel明显减轻了Isorel治疗组的手术免疫抑制作用,增加了NK细胞,T细胞和B细胞(尤其是T辅助细胞),补体,IgA,IgG和IgM的数量。与各个D0值进行比较。与对照组相比,Isorel治疗的患者的卡莫夫斯基状态和焦虑量表均有明显改善。结论:这项研究的结果表明围手术期使用槲寄生药物Isorel可以改善癌症患者的免疫能力和整体健康状况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号